The FDA’s approval of Wegovy on June 4, 2021, ended a seven-year drought in new obesity treatments and set off a chain reaction that has reshaped how doctors, patients, and insurers think about excess ...

Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction ...